Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade
Compose a Response to This Article
Other responses
No responses have been published for this article.